Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tango Therapeutics (TNGX) Return on Capital Employed: 2021-2025

Historic Return on Capital Employed for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to -0.54%.

  • Tango Therapeutics' Return on Capital Employed fell 11.00% to -0.54% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.54%, marking a year-over-year decrease of 11.00%. This contributed to the annual value of -0.45% for FY2024, which is 15.00% down from last year.
  • Tango Therapeutics' Return on Capital Employed amounted to -0.54% in Q3 2025, which was up 26.27% from -0.73% recorded in Q2 2025.
  • Tango Therapeutics' 5-year Return on Capital Employed high stood at -0.12% for Q3 2021, and its period low was -0.73% during Q2 2025.
  • Over the past 3 years, Tango Therapeutics' median Return on Capital Employed value was -0.38% (recorded in 2024), while the average stood at -0.43%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first climbed by 5bps in 2022, then tumbled by 35bps in 2025.
  • Tango Therapeutics' Return on Capital Employed (Quarterly) stood at -0.12% in 2021, then fell by 16bps to -0.28% in 2022, then fell by 3bps to -0.31% in 2023, then decreased by 18bps to -0.49% in 2024, then declined by 11bps to -0.54% in 2025.
  • Its Return on Capital Employed stands at -0.54% for Q3 2025, versus -0.73% for Q2 2025 and -0.56% for Q1 2025.